BeOne Medicines Ltd (ONC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in BeOne Medicines Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

BeOne Medicines Ltd (ONC) has returned -2.25% so far this year and 9.11% over the past 12 months. Looking at the last ten years, ONC has achieved an annualized return of 26.10%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Feb 3, 2016, ONC's average daily return is +0.15%, while the average monthly return is +2.98%. At this rate, your investment would double in approximately 2.0 years.

Historically, 52% of months were positive and 48% were negative. The best month was Jul 2017 with a return of +56.6%, while the worst month was Oct 2018 at -26.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ONC closed higher 51% of trading days. The best single day was Nov 1, 2019 with a return of +37.0%, while the worst single day was May 11, 2022 at -15.7%.

BeOne Medicines Ltd has an annualized alpha of 30.31%, beta of 0.89, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since February 04, 2016.

• This stock captured 116.37% of S&P 500 Index gains but only 55.47% of its losses — a favorable profile for investors.
• R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ONC ranks 47 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for BeOne Medicines Ltd (ONC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the BeOne Medicines Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BeOne Medicines Ltd was 69.96%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current BeOne Medicines Ltd drawdown is 26.34%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of BeOne Medicines Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how BeOne Medicines Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.